The FDA has approved Enhertu (trastuzumab deruxtecan) for treating HR-positive, HER2-low, and ultralow metastatic breast cancer, offering new hope for patients with limited options. This targeted therapy, developed by AstraZeneca and Daiichi Sankyo, is designed to deliver chemotherapy directly to cancer cells while minimizing damage to healthy tissue. The approval expands Enhertu’s use beyond HER2-positive cases, addressing a broader range of breast cancer patients who previously had fewer treatment alternatives.
This milestone approval highlights the evolving landscape of precision medicine in oncology, allowing for more tailored treatments based on specific cancer characteristics. Experts believe that Enhertu’s effectiveness in HER2-low and ultralow cases could redefine how breast cancer is classified and treated. With its demonstrated ability to improve outcomes in metastatic cases, this therapy could significantly impact the way oncologists approach breast cancer treatment moving forward. Click for More Details
